Modified HyperCVAD Versus Bortezomib-HyperCAD in Patients With Relapsed/Refractory Multiple Myeloma

Despite the availability of novel treatments for multiple myeloma, resistance to chemotherapy inevitably develops. We retrospectively reviewed the outcomes of patients with relapsed and/or refractory disease treated with modified hyperCVAD (n = 15) or bortezomib-hyperCAD (n = 18). Effectiveness and safety outcomes were similar in each group, with the entire cohort of patients demonstrating an overall response rate of 42%.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Original Study Source Type: research

Related Links:

HIV- associated lymphomas (HAL) remain an important cause of morbidity and mortality in HIV patients, especially in the refractory setting. Hematopoietic cell transplantation (HCT) is considered a curative option for patients with refractory HAL.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Original Study Source Type: research
Combination regimens with anti-CD20 agents may improve outcomes of patients with relapsed or refractory B-cell malignancies, but comparative clinical evidence is limited. This review assessed the published evidence on the efficacy of anti-CD20 monoclonal antibodies in combination with chemotherapy in patients with relapsed or refractory chronic lymphocytic leukemia (CLL), follicular lymphoma (FL), or diffuse large B-cell lymphoma (DLBCL), using a rapid evidence assessment (REA) approach. MEDLINE ®, Embase® and the Cochrane Library were searched from January 1, 1997 to July 14, 2017 (English language only).
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Review Article Source Type: research
Publication date: Available online 3 April 2018 Source:Clinical Lymphoma Myeloma and Leukemia Author(s): Sabina Chiaretti, Elias Jabbour, Dieter Hoelzer The outcome of adult acute lymphoblastic leukemia (ALL) has substantially improved by adopting pediatric-inspired regimens, and approximately half of the patients are nowadays cured. The evaluation of minimal residual disease currently represents the most important prognostic indicator, which drives treatment algorithms, which include allogeneic stem cell transplantation (allo-SCT) allocation. Indeed, for high-risk patients, allo-SCT should be pursued as soon as possible,...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
"Society of Hematologic Oncology (SOHO) State of the Art Updates and Next Questions"-Treatment of ALL. Clin Lymphoma Myeloma Leuk. 2018 Apr 03;: Authors: Chiaretti S, Jabbour E, Hoelzer D Abstract The outcome of adult acute lymphoblastic leukemia (ALL) has substantially improved by adopting pediatric-inspired regimens, and approximately half of the patients are nowadays cured. The evaluation of minimal residual disease currently represents the most important prognostic indicator, which drives treatment algorithms, which include allogeneic stem cell transplantation (allo-SCT) allocation. Inde...
Source: Clinical Lymphoma and Myeloma - Category: Cancer & Oncology Authors: Tags: Clin Lymphoma Myeloma Leuk Source Type: research
Publication date: Available online 3 April 2018 Source:Clinical Lymphoma Myeloma and Leukemia Author(s): Sabina Chiaretti, Elias Jabbour, Dieter Hoelzer The outcome of adult Acute Lymphoblastic Leukemia (ALL) has substantially improved by adopting pediatric inspired regimens, and about half of the patients are nowadays cured. The evaluation of Minimal Residual Disease (MRD) currently represents the most important prognostic which drive treatment algorithm and which includes allogeneic stem cell transplantation (allo-SCT) allocation. Indeed, for high-risk patients, Stem Cell Transplantation (allo-SCT) should be pursued as ...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Publication date: Available online 31 March 2018 Source:Clinical Lymphoma Myeloma and Leukemia Author(s): Steven M. Bair, Anthony Mato, Jakub Svoboda Classical Hodgkin lymphoma (cHL) is one of the most common lymphomas in the Western world. Though the majority of patients are cured with standard frontline therapy, up to 20% of patients will have relapsed or refractory disease. Though the conventional approach to treatment has consisted of chemotherapy, radiation, and for those that relapse, autologous or allogeneic transplantation, newer approaches have become available in recent years, including immunoconjugates and chec...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Publication date: Available online 31 March 2018 Source:Clinical Lymphoma Myeloma and Leukemia Author(s): Takayoshi Tachibana, Taiki Andou, Masatsugu Tanaka, Satomi Ito, Takuya Miyazaki, Yoshimi Ishii, Eriko Ogusa, Hideyuki Koharazawa, Hiroyuki Takahashi, Kenji Motohashi, Jun Aoki, Yuki Nakajima, Kenji Matsumoto, Maki Hagihara, Chizuko Hashimoto, Jun Taguchi, Katsumichi Fujimaki, Hiroyuki Fujita, Shin Fujisawa, Heiwa Kanamori, Hideaki Nakajima A multicenter retrospective analysis was performed to evaluate the clinical significance of serum ferritin at diagnosis in patients with acute myeloid leukemia. The study cohort inc...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Classical Hodgkin lymphoma (cHL) is one of the most common lymphomas in the Western world. Though the majority of patients are cured with standard frontline therapy, up to 20% of patients will have relapsed or refractory disease. Though the conventional approach to treatment has consisted of chemotherapy, radiation, and for those that relapse, autologous or allogeneic transplantation, newer approaches have become available in recent years, including immunoconjugates and checkpoint inhibitors. These approaches have demonstrated significant efficacy in clinical trials and may be associated with fewer long-term toxicities com...
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Review Article Source Type: research
Conclusion Intensified chemotherapy protocols for adult ALL have succeeded in achieving better survival rates in adults, especially younger adults. The low overall survival found with GMALL in Brazil's public hospital denotes the importance of optimizing the adaptations of international protocols for treatment of ALL in nondeveloped countries and, in parallel, improving supportive care in public services. Micro-Abstract Studying adult acute lymphoblastic leukemia (ALL) in developing countries is essential, because few reports are available. We performed a retrospective medical record review of the adapted German Multicente...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Classical Hodgkin lymphoma (cHL) is one of the most common lymphomas in the Western world. Although most patients are cured with standard first-line therapy, up to 20% of patients will have relapsed or refractory disease. Although the conventional approach to treatment has consisted of chemotherapy, radiation, and for those who relapse, autologous or allogeneic transplantation, newer approaches have become available in recent years, including immunoconjugates and checkpoint inhibitors. These approaches have shown significant efficacy in clinical trials and might be associated with fewer long-term toxicities compared with c...
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Review Source Type: research
More News: Chemotherapy | Hematology | Leukemia | Lymphoma | Myeloma | Study | Velcade